Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -57.74% is 60% above its 5-year average of -142.57%, near the high end of its 5-year range (-237.69%–-28.09%).
49.69% above its 12-month average of -114.78%.
Reported quarterly return on assets; no daily interpolation. Q1 FY2027 (2026-06-30): -21.87%.
RETURN ON ASSETS (ROA)
-57.74%
RETURN ON ASSETS (ROA) AVG TTM
-114.78%
RETURN ON ASSETS (ROA) AVG 3Y
-140.32%
RETURN ON ASSETS (ROA) AVG 5Y
-142.57%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+49.69%
CURRENT VS 3Y AVG
+58.85%
CURRENT VS 5Y AVG
+59.50%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.27%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
-78.96%
vs the sector median at left
Valion Bio, Inc.
Market Cap
$9.86M
Return on Assets (ROA)
-57.74%
TTM Avg
-114.78%
3Y Avg
-140.32%
5Y Avg
-142.57%
Market Cap
$9.83M
Return on Assets (ROA)
-115.57%
TTM Avg
-131.41%
3Y Avg
-121.81%
5Y Avg
-149.86%
Market Cap
$9.75M
Return on Assets (ROA)
-108.85%
TTM Avg
-94.23%
3Y Avg
-71.21%
5Y Avg
-107.74%
Market Cap
$9.71M
Return on Assets (ROA)
-52.23%
TTM Avg
-58.24%
3Y Avg
-82.00%
5Y Avg
-104.09%
Market Cap
$10.06M
Return on Assets (ROA)
-204.84%
TTM Avg
-224.84%
3Y Avg
-332.29%
5Y Avg
-789.37%
Market Cap
$10.06M
Return on Assets (ROA)
-149.72%
TTM Avg
-86.94%
3Y Avg
-66.39%
5Y Avg
-60.64%
Market Cap
$10.13M
Return on Assets (ROA)
-148.79%
TTM Avg
-109.24%
3Y Avg
-211.74%
5Y Avg
-146.61%
Market Cap
$9.50M
Return on Assets (ROA)
-73.89%
TTM Avg
-61.17%
3Y Avg
-50.83%
5Y Avg
-128.36%
Market Cap
$10.21M
Return on Assets (ROA)
-88.09%
TTM Avg
-90.94%
3Y Avg
-60.82%
5Y Avg
-50.49%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Valion Bio, Inc. (VBIO) | $9.86M | -57.74% | -114.78% | -140.32% | -142.57% |
| NeuroOne Medical Technologies Corporation (NMTC)vs › | $9.83M | -115.57% | -131.41% | -121.81% | -149.86% |
| MetaVia Inc. (MTVA)vs › | $9.75M | -108.85% | -94.23% | -71.21% | -107.74% |
| Satellos Bioscience Inc. (MSLE)vs › | $9.71M | -52.23% | -58.24% | -82.00% | -104.09% |
| Medicus Pharma Ltd. Common Stock (MDCX)vs › | $10.06M | -204.84% | -224.84% | -332.29% | -789.37% |
| Senti Biosciences, Inc. (SNTI)vs › | $10.06M | -149.72% | -86.94% | -66.39% | -60.64% |
| Tvardi Therapeutics, Inc. (TVRD)vs › | $10.13M | -148.79% | -109.24% | -211.74% | -146.61% |
| Ainos, Inc. (AIMD)vs › | $9.50M | -73.89% | -61.17% | -50.83% | -128.36% |
| Lifeward Ltd. (LFWD)vs › | $10.21M | -88.09% | -90.94% | -60.82% | -50.49% |
| Adial Pharmaceuticals, Inc. (ADIL)vs › | $10.45M | -198.70% | -189.50% | -187.22% | -200.18% |
ROA
-57.7%
ROE
-157.8%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -28.09% |
| 2024-12-31 | -201.46% |
| 2023-12-31 | -159.86% |
| 2022-12-31 | -171.85% |
| 2021-12-31 | -56.49% |
| 2020-12-31 | -237.69% |
| 2019-12-31 | -137.17% |
